GSK 4172239
Alternative Names: GSK-4172239; GSK-4172239DLatest Information Update: 28 Apr 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antianaemics
- Mechanism of Action DNA cytosine 5 methyltransferase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Sickle cell anaemia
Most Recent Events
- 25 Feb 2023 Phase-I clinical trials in Sickle cell anaemia (In adults, Treatment experienced) in USA (PO) (NCT05660265)
- 27 Dec 2022 Preclinical trials in Sickle cell anaemia in United Kingdom (PO)
- 21 Dec 2022 GlaxoSmithKline plans a phase I trial for Sickle cell anaemia (In adults, Treatment experienced) (PO), (NCT05660265)